Nhu Bruce, MD
Vascular Neurology · Shenandoah, TXNPI 1609922210
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 95.0% of the total across 577 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 56 manufacturers, the largest accounting for just 19.0% — the pattern of someone who eats at a lot of different presentations.
Across 577 payments — averaging $17.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Novartis$1K
- Pfizer$757
- Janssen Research & Development, LLC$731
- AstraZeneca$629
- Teva Pharmaceuticals USA, Inc.$438
- plus $5K from 50 others
Across 32 payments — averaging $6218.72 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Janssen Research & Development, LLC$199K
What the payments were for
- Travel & lodging$2923%
- Food & beverage$9,79795%
- Education$2202%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
How this compares
$10,309 in reported general payments places this provider in the 80th percentile of 76 vascular neurology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 20 | $337,111 |
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 11 | $101,601 |
| NuplazidPimavanserin Tartrate | 13 | $73,174 |
| RytaryCarbidopa/Levodopa | 37 | $49,298 |
| GlatopaGlatiramer Acetate | 22 | $47,765 |
| RexultiBrexpiprazole | 32 | $46,153 |
| Glatiramer Acetate | 18 | $40,220 |
| Trokendi XrTopiramate | 13 | $28,020 |
| QuliptaAtogepant | 22 | $23,445 |
| Repatha SureclickEvolocumab | 22 | $18,389 |
| Oxtellar XrOxcarbazepine | 14 | $18,151 |
| Aimovig AutoinjectorErenumab-Aooe | 12 | $13,281 |
| Memantine Hcl | 431 | $12,850 |
| Nurtec OdtRimegepant Sulfate | 12 | $12,694 |
| FycompaPerampanel | 11 | $9,919 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid | $26 | $337,11120 claims |
| Grifols USA, LLCGamunex-C | $247 | $101,60111 claims |
| Acadia Pharmaceuticals IncNuplazid | $112 | $73,17413 claims |
| Amneal Pharmaceuticals LLCRytary, Pyridostigmine Bromide | $91 | $51,87481 claims |
| Supernus Pharmaceuticals, Inc.Trokendi Xr, Oxtellar Xr | $92 | $46,17127 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $19 | $46,15332 claims |
| AbbVieQulipta | $1,954 | $23,44522 claims |
| PfizerNurtec Odt | $757 | $12,69412 claims |
| Eisai Inc.Fycompa | $60 | $9,91911 claims |
| Johnson & JohnsonXarelto | $312 | $8,85312 claims |
| Upsher-smith Laboratories LLCTopiramate | $121 | $91377 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 76 vascular neurology providers in Texas.
Other vascular neurology in Shenandoah
- Nishant RanawatShenandoah$6K
- Shyam PanchalShenandoah$780
- Keval ShahShenandoah$719
- Ameer HassanHarlingen$1M
- John VolpiHouston$407K
- Lee BirnbaumSan Antonio$195K
- Amrou SarrajHouston$182K
- Sunil ShethHouston$54K
- Steven WarachAustin$32K
- Jefferson MileyAustin$28K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.